Amgen Inc. (AMGN) Now Covered by Royal Bank Of Canada

Investment analysts at Royal Bank Of Canada assumed coverage on shares of Amgen Inc. (NASDAQ:AMGN) in a report released on Thursday, September 14th, Marketbeat Ratings reports. The brokerage set a “sector perform” rating and a $192.00 price target on the medical research company’s stock. Royal Bank Of Canada’s target price suggests a potential upside of 3.36% from the stock’s current price.

A number of other analysts have also recently commented on the company. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research report on Friday, June 30th. BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. Jefferies Group LLC reissued a “hold” rating and set a $180.00 price target on shares of Amgen in a report on Monday, May 22nd. Credit Suisse Group set a $177.00 price target on Amgen and gave the company a “hold” rating in a report on Friday, July 14th. Finally, Morgan Stanley upped their price objective on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $186.14.

Shares of Amgen (AMGN) traded down 0.47% on Thursday, hitting $185.76. 2,275,630 shares of the stock traded hands. The stock has a 50 day moving average of $175.99 and a 200-day moving average of $169.31. The stock has a market cap of $135.54 billion, a PE ratio of 16.92 and a beta of 1.35. Amgen has a 1-year low of $133.64 and a 1-year high of $191.10.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the business earned $2.84 earnings per share. The company’s revenue was up 2.1% on a year-over-year basis. On average, equities research analysts expect that Amgen will post $12.57 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Amgen Inc. (AMGN) Now Covered by Royal Bank Of Canada” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://stocknewstimes.com/2017/09/23/amgen-inc-amgn-coverage-initiated-at-royal-bank-of-canada.html.

Several institutional investors have recently bought and sold shares of the company. Bogart Wealth LLC boosted its position in shares of Amgen by 13.8% in the 2nd quarter. Bogart Wealth LLC now owns 3,181 shares of the medical research company’s stock worth $548,000 after purchasing an additional 385 shares in the last quarter. Intl Fcstone Inc. acquired a new stake in shares of Amgen in the 2nd quarter worth $1,769,000. Gs Investments Inc. acquired a new stake in shares of Amgen in the 2nd quarter worth $2,119,000. Lord Abbett & CO. LLC acquired a new stake in shares of Amgen in the 2nd quarter worth $14,175,000. Finally, United Bank VA boosted its position in shares of Amgen by 7.4% in the 2nd quarter. United Bank VA now owns 28,581 shares of the medical research company’s stock worth $4,923,000 after purchasing an additional 1,960 shares in the last quarter. 78.09% of the stock is owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply